ATE486125T1 - Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren - Google Patents

Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren

Info

Publication number
ATE486125T1
ATE486125T1 AT03790358T AT03790358T ATE486125T1 AT E486125 T1 ATE486125 T1 AT E486125T1 AT 03790358 T AT03790358 T AT 03790358T AT 03790358 T AT03790358 T AT 03790358T AT E486125 T1 ATE486125 T1 AT E486125T1
Authority
AT
Austria
Prior art keywords
dendritic cells
tumor
cells
partially matured
administration
Prior art date
Application number
AT03790358T
Other languages
English (en)
Inventor
Marnix Bosch
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Application granted granted Critical
Publication of ATE486125T1 publication Critical patent/ATE486125T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03790358T 2002-12-06 2003-12-05 Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren ATE486125T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43126702P 2002-12-06 2002-12-06
PCT/US2003/038672 WO2004053072A2 (en) 2002-12-06 2003-12-05 Administration of dendritic cells partially matured in vitro for the treatment of tumors

Publications (1)

Publication Number Publication Date
ATE486125T1 true ATE486125T1 (de) 2010-11-15

Family

ID=32507696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03790358T ATE486125T1 (de) 2002-12-06 2003-12-05 Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren

Country Status (18)

Country Link
US (2) US20060057120A1 (de)
EP (2) EP1567155B1 (de)
JP (2) JP4859169B2 (de)
KR (1) KR101144196B1 (de)
CN (2) CN102600461B (de)
AT (1) ATE486125T1 (de)
AU (2) AU2003293411B2 (de)
BR (1) BRPI0317064B8 (de)
CA (1) CA2509058A1 (de)
DE (1) DE60334725D1 (de)
DK (1) DK1567155T3 (de)
ES (1) ES2354944T3 (de)
IL (1) IL169002A (de)
MX (1) MXPA05006042A (de)
PL (1) PL377209A1 (de)
PT (1) PT1567155E (de)
RU (1) RU2348418C2 (de)
WO (1) WO2004053072A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486125T1 (de) * 2002-12-06 2010-11-15 Northwest Biotherapeutics Inc Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren
EP1720567A2 (de) * 2004-02-10 2006-11-15 Innate Pharma Zusammensetzung und verfahren zur behandlung von karzinomen
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
US8076132B2 (en) 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2007001200A1 (en) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Mature dendritic cells loaded with tumor polylysates and antitumoral vaccine base thereon
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
EP2072617A1 (de) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Verfahren zur Herstellung dendritischer Zellen
RU2361598C1 (ru) * 2008-02-18 2009-07-20 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, индуцирующее созревание дендритных клеток
AU2009228215B2 (en) * 2008-03-27 2015-12-10 Asterias Biotherapeutics, Inc. Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
US8679834B2 (en) * 2009-07-09 2014-03-25 TiGenix S.A.U Methods and compositions for use in cellular therapies
RU2565542C2 (ru) * 2010-02-10 2015-10-20 Иммуникум Аб Улучшенная композиция для ингибирования пролиферации опухолевых клеток
EP2547360A4 (de) * 2010-03-15 2013-11-20 Univ Pennsylvania System und verfahren zur herstellung und lagerung aktivierter reifer dendritischer zellen
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
SG11201510552WA (en) * 2012-06-27 2016-01-28 Hasumi Internat Res Foundation Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10
GB201300049D0 (en) * 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
EA201690912A1 (ru) 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
CA2990640A1 (en) * 2015-06-30 2017-01-05 Northwest Biotherapeutics, Inc. Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
AU2016323066B2 (en) * 2015-09-15 2023-04-27 Northwest Biotherapeutics, Inc Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
KR101749165B1 (ko) * 2016-06-07 2017-06-23 충남대학교산학협력단 Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물
US12059434B2 (en) 2017-02-28 2024-08-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated DC1s and methods for their production and use
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
EP4520334A1 (de) 2023-09-07 2025-03-12 Mnemo Therapeutics Verfahren und zusammensetzungen zur verbesserung der immunreaktion
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
ATE260971T1 (de) 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
DE69840739D1 (de) * 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
IL141990A0 (en) * 1998-09-15 2002-03-10 Univ Pittsburgh Antigen presenting cells with genetically enhanced cytokine expression
AU756260B2 (en) * 1998-10-02 2003-01-09 Mitsubishi Chemical Corporation Method for inducing cellular immunity and cells with induced cellular immunity
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
WO2000061132A1 (en) * 1999-04-14 2000-10-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
AU2403901A (en) * 1999-12-28 2001-07-09 Ichiro Azuma Maturation-promoting agent for immature dendritic cells
US20030175247A1 (en) * 2000-05-12 2003-09-18 Michael Salgaller Method to increase class I presentation of exogenous antigens by human dendritic cells
JP2002069001A (ja) * 2000-08-29 2002-03-08 Asahi Kasei Corp 樹状細胞を主成分とする細胞ワクチン
ES2234928T3 (es) * 2000-11-14 2005-07-01 Universite Libre De Bruxelles Generacion y uso de celulas dendriticas.
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
WO2003010292A2 (en) 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
ES2766299T3 (es) * 2001-09-06 2020-06-12 Northwest Biotherapeutics Inc Composiciones y procedimientos para la activación linfocitaria de células dendríticas monocíticas y células T para generar una respuesta Th-1
ATE486125T1 (de) * 2002-12-06 2010-11-15 Northwest Biotherapeutics Inc Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren
JP4762887B2 (ja) * 2003-02-27 2011-08-31 ノースウエスト バイオセラピューティクス，インコーポレイティド 付加的なサイトカインの非存在下でｇｍ−ｃｓｆを用いる単球樹状前駆細胞からの樹状細胞の産生

Also Published As

Publication number Publication date
EP1567155A2 (de) 2005-08-31
AU2003293411A1 (en) 2004-06-30
ES2354944T3 (es) 2011-03-21
CN1738619B (zh) 2012-04-18
EP1567155A4 (de) 2006-12-13
AU2011200352A1 (en) 2011-02-17
AU2003293411B2 (en) 2010-10-28
US20120251561A1 (en) 2012-10-04
JP5707284B2 (ja) 2015-04-30
EP2260861A1 (de) 2010-12-15
BR0317064A (pt) 2005-10-25
JP2011246493A (ja) 2011-12-08
WO2004053072A2 (en) 2004-06-24
JP2006510667A (ja) 2006-03-30
RU2005121256A (ru) 2006-02-10
JP4859169B2 (ja) 2012-01-25
CN102600461B (zh) 2017-07-14
US20060057120A1 (en) 2006-03-16
WO2004053072A3 (en) 2005-06-16
DE60334725D1 (de) 2010-12-09
KR101144196B1 (ko) 2012-05-21
EP1567155B1 (de) 2010-10-27
IL169002A (en) 2015-01-29
BRPI0317064B8 (pt) 2021-05-25
BRPI0317064B1 (pt) 2020-11-03
PL377209A1 (pl) 2006-01-23
CA2509058A1 (en) 2004-06-24
DK1567155T3 (da) 2011-02-14
CN1738619A (zh) 2006-02-22
MXPA05006042A (es) 2005-09-21
CN102600461A (zh) 2012-07-25
AU2011200352B2 (en) 2013-06-27
HK1082180A1 (en) 2006-06-02
RU2348418C2 (ru) 2009-03-10
PT1567155E (pt) 2011-01-28
KR20050084189A (ko) 2005-08-26

Similar Documents

Publication Publication Date Title
ATE486125T1 (de) Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren
Okamoto et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation
Bilsborough et al. Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties
Han et al. Vitamin E supplementation increases T helper 1 cytokine production in old mice infected with influenza virus
Lazarski et al. IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance
Ito et al. TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4
Handel-Fernandez et al. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice.
CA2483012A1 (en) Oligonucleotide compositions and their use for the modulation of immune responses
Salio et al. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells
EA200401405A1 (ru) Модифицированный осповакцинный вирус анкара для вакцинации новорожденных
DK0585943T3 (da) Opløselige ligander for CD40
Hotz et al. Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
Habibi et al. Cytokine gene expression in healing and non‐healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi‐quantitative RT–PCR
JP2019509264A (ja) ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法
Zeng et al. Natural killer cells play a key role in the antitumor immunity generated by chaperone‐rich cell lysate vaccination
MX2023001622A (es) Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
Holzer et al. Haptens as drugs: contact allergens are powerful topical immunomodulators
Valaperti et al. Vaccination with Flt3L-induced CD8α+ dendritic cells prevents CD4+ T helper cell-mediated experimental autoimmune myocarditis
ATE381942T1 (de) Mittel zur behandlung von infektionen mit leishmanien
Saito et al. Characterization of the indirect antitumor effect of γ-interferon using ascites-associated macrophages in a human tumor clonogenic assay
Enioutina et al. The induction of systemic and mucosal immunity to protein vaccines delivered through skin sites exposed to UVB
DE60135232D1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
KR20200144060A (ko) 건강한 사람의 면역세포 배양액을 이용한 nk 세포의 함량을 증진시키는 방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1567155

Country of ref document: EP